Kamal Hamed

This profile gathers the share dealings of Kamal Hamed in Spero Therapeutics, Inc. The record holds 6 filings, for trades running from 12 September 2022 to 2 February 2024.

Sales make up the whole of the open-market record (2 sales, €82k). Other entries cover 4 share grants. 2024 to date brings no purchases and 1 sale.

The newest entry dates from 5 February 2024: an open-market sale of €35k, in Spero Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.